Assembly BiosciencesASMB -1.69%31 3-Year EBITDA Growth Rate is 64.20% as of Mar. 2026, which is 209% above its 10-year median of 20.80. GuruFocus rates ASMB with a GF Score™ of 31/100. The stock has 3 warning signs investors should review. Among 1,137 Biotechnology companies, Assembly Biosciences ranks better than 91.47% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 64.20% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 42.20% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 20.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Assembly Biosciences was 64.20% per year. The lowest was -28.90% per year. And the median was 20.80% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Assembly Biosciences 3-Year EBITDA Growth Rate Related Terms
ASMB vs CTNM, PRTA, RGNX: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, Assembly Biosciences's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Assembly Biosciences 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Assembly Biosciences's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Assembly Biosciences's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 64.20% mean?
Assembly Biosciences (ASMB) has a 3-Year EBITDA Growth Rate of 64.20% as of Mar. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Assembly Biosciences and its competitors. This is 209% above median its historical median of 20.80. According to the industry distribution chart, Assembly Biosciences ranks #97 out of 1137 companies in the Biotechnology industry, placing it in the top 8.5%.
Is Assembly Biosciences' 3-Year EBITDA Growth Rate too high?
Assembly Biosciences' current 3-Year EBITDA Growth Rate of 64.20% is 209% above median its 10-year median of 20.80. The Biotechnology industry median 3-Year EBITDA Growth Rate is 14.90. Assembly Biosciences' value of 64.20% is 330.9% above this industry median. Based on the distribution chart, Assembly Biosciences ranks #97 out of 1137 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Assembly Biosciences has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Assembly Biosciences' 3-Year EBITDA Growth Rate compare to CTNM and PRTA?
According to the Biotechnology industry distribution chart, Assembly Biosciences ranks #97 out of 1137 companies for 3-Year EBITDA Growth Rate. This places Assembly Biosciences in the top 9% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 14.90. Assembly Biosciences' value of 64.20% is 330.9% above this benchmark. While the company's 10-year median is 20.80 vs. the industry median of 14.90, Assembly Biosciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.90, based on 1,137 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Assembly Biosciences's current 3-Year EBITDA Growth Rate of 64.20% is 330.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Assembly Biosciences and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Assembly Biosciences's current 3-Year EBITDA Growth Rate is 64.20%, which is 209% above median its own 10-year median of 20.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Assembly Biosciences stock overvalued right now?
Assembly Biosciences (ASMB) has a current 3-Year EBITDA Growth Rate of 64.20%. The current 3-Year EBITDA Growth Rate is 64.20%, which is 209% above median its 10-year median of 20.80 and 330.9% above the Biotechnology industry median of 14.90. Assembly Biosciences' overall GF Score™ is 31/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Assembly Biosciences (ASMB), the current 3-Year EBITDA Growth Rate is 64.20% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Assembly Biosciences Inc is a clinical-stage biotechnology company. The Company's pipeline includes multiple clinical-stage investigational therapies, including: (1) two long-acting helicase-primase inhibitors (HPI) for the treatment of recurrent genital herpes; (2) an orally bioavailable hepatitis delta virus entry inhibitor; and (3) a potent next-generation capsid assembly modulator designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. The Company's pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) for the treatment of transplant-related herpesviruses.
31GF Score
Get the complete analysis for ASMB
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASMB has been successfully added to your 